Furthermore, the MYH9/AKT axis influences how ccRCC cells respond to Sunitinib treatment and may serve as a biomarker for assessing the benefit of Sunitinib in ccRCC patients (Xu et al., 2022). Here, MYH9 is linked to nonpapillary renal cell carcinoma.